Mankind Pharma share price: block deals and NCD plan 2026

Share price snapshot: why different levels show up

Mankind Pharma Ltd (NSE: MANKIND) has been moving sharply across sessions as multiple block deals and stake sale reports hit the tape. One data point in circulation put the share price at ₹2,125 as on 17 April 2026. Separately, during an active session the stock was reported at ₹2,228.7, up 1.94% on NSE at 12:44 IST, extending gains for a fifth straight session.

These variations are typical when quotes are pulled from different timestamps, exchanges, or market segments, especially on days with heavy institutional activity. The stock has also been flagged as volatile, with prices changing through the day based on broader market conditions and trade flows.

Fifth straight session gain, futures also higher

In the same intraday update that cited a fifth consecutive rise, the benchmark December futures contract for Mankind Pharma was reported at ₹2,231.3, up 2.1% on the day. Futures prices often track spot moves but can reflect incremental positioning around anticipated supply from large sellers or demand from buyers.

The combination of spot strength and a higher futures quote suggested continued near-term participation despite headlines around stake exits.

Block deals take centre stage

A large part of the stock’s recent volatility has been attributed to block deals and reported stake sales by financial investors. In one report, Mankind Pharma shares dropped more than 4%, falling as much as 4.37% to ₹2,117 on BSE in morning trade on a Tuesday. The same coverage also mentioned an opening dip to ₹2,141.5 in early trade.

Trading activity spiked alongside the price move. The number of shares exchanging hands on BSE was reported at almost 41 times the daily average. On NSE, the volume was cited at 14,386,691 shares, far above a 20-day average of 3.81 lakh shares.

Size of the deal: shares, equity and value

Data cited in the coverage said around 1.3 crore shares, translating into 3.2% equity, changed hands in a block deal worth ₹2,736.8 crore. Another related update in Hindi reported multiple block deals in which 2.97% equity (1.17 crore shares) changed hands, after which the stock fell more than 3% and touched ₹2,117 on NSE.

There was also a separate account of a heavier sell-off where more than 2.15 crore shares traded on NSE around 9:40 am, with traded value of ₹3,964.18 crore at that time.

Who sold: ChrysCapital affiliate, Capital Group affiliate, and others

Reports linked the selling to private equity and institutional investors. A ChrysCapital affiliate entity, Beige Ltd, was reported to have issued a term sheet via its broker to sell up to 1.16 crore shares in a price band of ₹2,103.21 to ₹2,214 per share. This was described as being at a discount of up to 5% to the previous close of ₹2,212.55.

Separately, a Capital Group affiliate, Hema CIPEF (I), was reported to have sold 0.46% stake at ₹2,082 apiece, with a total deal value of ₹385 crore. Another report also indicated that Hema CIPEF (I) likely sold 0.9% of Mankind Pharma, while noting that official parties to some transactions were undisclosed.

A Canada Pension Plan-related transaction was also referenced, stating it took home about ₹256 crore through a stake sale and held 1.47% equity at the end of the March quarter.

Fundraising headline: up to ₹10,000 crore via NCDs and CP

Alongside the trading activity, Mankind Pharma announced it would raise up to ₹10,000 crore through the issuance of non-convertible debentures (NCDs) and commercial papers. The fundraising plan is a separate corporate action from the secondary-market stake sales, but it can influence sentiment because it signals the company’s intent to access debt markets.

Valuation and longer-term price context

The stock’s P/E was reported at 54.2 based on TTM earnings ending September 25. Performance figures in the same roundup showed Mankind Pharma was down 23.43% over the last one year, compared with a 10.32% rise in NIFTY and a 1.52% rise in the Nifty Pharma index.

Another price history snapshot stated that as on 12 Nov 2025, the share price was ₹2,235.2, down 7.18% over six months and down 15.55% over one year, with a 52-week low of ₹2,115.1 and a 52-week high of ₹3,054.8.

Broader market backdrop: block-deal heavy week

The broader market context also mattered. Nifty was reported to have closed the week with 2% gains, even as block deals totalled ₹10,934 crore across large-, mid- and small-cap companies. Trent led large-cap block deals at ₹715 crore, followed by Mankind Pharma, Tube Investments of India, Bosch and others, according to the same roundup.

Key numbers table

Another trading snapshot: price and turnover data

One separate market snapshot listed the “current price” of MANKIND as ₹2,454.90, down 1.04% over the past 24 hours. It also showed traded volume at 0.48 lakh and traded value of ₹11.67 crore under “Trade Information”. Because such snapshots can be captured at different times, they are best read as point-in-time indicators rather than a single definitive close.

What investors are watching next

For investors tracking Mankind Pharma, the key near-term drivers highlighted in the coverage are the pace and pricing of stake sales, the disclosed or undisclosed identity of buyers and sellers in block deals, and how the stock absorbs large one-off supply. On the corporate side, the proposed ₹10,000 crore debt fundraising through NCDs and commercial papers is a clear headline, though details such as timing and tranches were not specified in the provided information.

The stock’s recent pattern of sharp intraday drops and recoveries, combined with heavy volumes, keeps focus on exchange disclosures around block transactions and any further stake reductions by financial investors.